Table of Contents

Section I: General Information

Chapter 1  EMA and Other Regulatory Bodies ................................................................. 1
  Updated by Ratinder Dhani, MSRA, RAC

Chapter 2  History of Regulations .................................................................................. 13
  Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS

Chapter 3  Overview of Drug and Biologic Regulatory Pathways .................................. 31
  Updated by Kathrin Schalper, PhD, RAC

Chapter 4  Preparing for EMA Meetings Prior to Submission of a Marketing Authorisation Application ...... 41
  Updated by Kell Cannon, Kate Dion and Cindy DiBiasi

Chapter 5  Preparing for EMA Meetings During Review of a Marketing Authorisation Application .......... 53
  By Kell Cannon, Kate Dion and Cindy DiBiasi

Chapter 6  Pricing and Reimbursement ........................................................................... 61
  Updated by Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 7  Health Technology Assessment (HTA) ........................................................... 77
  Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC

Chapter 8  The Paediatric Regulation ................................................................................ 93
  Updated by Karl-Heinz Huemer, PhD, MD

Chapter 9  Advertising and Promotion ............................................................................ 103
  Updated by Karen Zhou, JD, MS, RAC

Chapter 10 Enforcement and Competent Authorities ..................................................... 115
  Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS

Chapter 11 Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery ................................................................. 121
  Updated by Yolanda García Barruso

Chapter 12 Regulatory Strategy ..................................................................................... 135
  Updated by Karen Fan, MSc, PEng, RAC

Section II: Medical Devices

Chapter 13 The New Medical Devices Regulation and In Vitro Diagnostic Medical Devices Regulation ...... 141
  Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LLM

Chapter 14 The European Medical Devices Legal System ................................................ 151
  Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LLM
Chapter 15  Medical Devices: Legislation and Classification

Updated by Ruthanne Vendy, RAC and Chaunceen Leab Wood, MS, RAC

Chapter 16  In Vitro Diagnostic Medical Devices

Updated by Erik Vollebregt, LLM

Chapter 17  General Safety and Performance Requirements and Technical Documentation
(EU MDR, EU IVDR)

Updated by Darin Oppenheimer, DRSc, RAC, Suraj Ramachandran, MS, RAC and George Cusatis, MS, RAC

Chapter 18  Medical Device Preclinical Testing

Updated by Jan-Paul van Loon, MSc, PhD and Gert Bos, MSc, PhD, FRAPS

Chapter 19  Clinical Evaluation and Clinical Investigations

Updated by Loes Pelgrim, MSc and Gert Bos, MSc, PhD, FRAPS

Chapter 20  Medical Device Conformity Assessment Procedure

Updated by Gert Bos, MSc, PhD, FRAPS

Chapter 21  Medical Device Compliance: Postmarket Requirements

Updated by Tran Do and Gert Bos, MSc, PhD, FRAPS

Chapter 22  Medical Device National Particularities

Updated by Robert Falcone, PhD

Section III: Medicinal Products

Chapter 23  Overview of Authorisation Procedures for Medicinal Products

Updated by Sharry Arora, MPharm

Chapter 24  Adaptive and Alternative Pathways

Updated by Kathrin Schalper, PhD, RAC

Chapter 25  Preclinical Testing and Good Laboratory Practice Regulations

Updated by Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 26  Medicinal Product Clinical Trials

Updated by Ashley Clark, MSc, RAC

Chapter 27  Registration Procedures for Medicinal Products

Updated by Jocelyn Jennings, MS, RAC

Chapter 28  Quality Systems and Inspectorate Process—Pharmaceuticals

Updated by Treena Jackson, MS, MA, CQA, CSSGB, RAC and Siegfried Schmitt, PhD

Chapter 29  Generic Medicinal Products

Updated by Nicole Beard MS, PhD

Chapter 30  Biosimilar Medicinal Products

Updated by Jocelyn Jennings, MS, RAC

Chapter 31  Nonprescription Medicinal Products

Updated by Nicole Beard MS, PhD
Chapter 32 Marketing Authorisations for Products Derived From Biotechnology ..................................................413
Updated by Jocelyn Jennings, MS, RAC

Chapter 33 Pharmaceutical Postauthorisation Requirements and Compliance With the Marketing Authorisation ............................................423
Updated by Sharry Arora, MPharm

Chapter 34 Pharmacovigilance ...........................................................................................................................................437
Updated by Jocelyn Jennings, MS, RAC

Chapter 35 Regulatory Framework for Advanced Therapy Medicinal Products ................................................451
By Daniela Drago, PhD, RAC, Florence Houn, MD, MPH and James McBlane, PhD

Chapter 36 Human Tissue Regulation ...........................................................................................................................471
Updated by Nicole Beard, MSc, PhD

Chapter 37 Vaccines ............................................................................................................................................489
Updated by Frédéric Béard

Section IV: Foods
Chapter 38 Food Supplements ...........................................................................................................................501
Updated by Manfred Ruthsatz, PhD, RAC, FRAPS

Chapter 39 Food for Special Medical Purposes ..................................................................................................511
Updated by Manfred Ruthsatz, PhD, RAC, FRAPS

Section V: Other Product Classifications
Chapter 40 Products Manufactured From Human Blood or Plasma ..................................................................519
Updated by Nicole Beard, MSc, PhD

Chapter 41 Orphan Medicinal Products ............................................................................................................529
Updated by Jocelyn Jennings, MS, RAC

Chapter 42 Combination Products .....................................................................................................................543
Updated by Claudia Ising, FRAPS, RAC

Section VI: Resources
Chapter 43 Regulatory Information Resources ...................................................................................................553
Updated by Meredith Brown-Tuttle, FRAPS and Gert Bos, MSc, PhD, FRAPS

Appendices
Comparative Matrix of EU Legislation Across Product Lines ..................................................................................575
Glossary .................................................................................................................................................................623
Index .................................................................................................................................................................643

Figures
Figure 1-1. EMA Mission ........................................................................................................................................3
Figure 1-2. EMA Organisational Structure ....................................................................................................9
Figure 5-1. Approximate Representation of Key CHMP, CAT and PRAC Feedback and Meetings Based on Standard Assessment Review Timeline ......................................................................................55
Figure 5-2. Example Timeline for CHMP Meeting Preparation ............................................................................57
Table 20-4. IVDD Conformity Assessment Documentation ................................................................. 247
Table 20-5. Internal Production Control ......................................................................................... 254
Table 20-6. EC Type-Examination ................................................................................................. 254
Table 20-7. Production Quality Assurance .................................................................................... 254
Table 20-8. Product Quality Assurance ......................................................................................... 254
Table 20-9. Product Verification ................................................................................................... 254
Table 20-10. Full Quality Assurance System ................................................................................254
Table 20-11. Authorised Representatives......................................................................................255
Table 21-1. Provisions for Providing Feedback about Medical Devices ........................................259
Table 21-2. Eudamed Data Repository ..........................................................................................262
Table 21-3. Comparison of Safeguard Clause and Health Monitoring Measures .........................267
Table 22-1. EU Outermost Regions ...............................................................................................272
Table 22-2. Current Directives and New Regulations for Medical Devices, AIMDs and IVDs ..........272
Table 22-3. Translation Requirements for Medical Devices, AIMDs and IVDs ...............................273
Table 22-4. National Languages of the EU, Iceland, Liechtenstein and Norway ..........................274
Table 23-1. Standard Timetable for Evaluation of a Centralised Application .................................284
Table 23-2. Mutual Recognition Procedure Flowchart .................................................................287
Table 23-3. Decentralised Procedure Flowchart ..........................................................................290
Table 26-1. Summary of Selected Significant Changes Under Regulation (EU) No. 536/2014 (ECTR) ................................................................................................................ 314
Table 26-2. Definitions of Selected Clinical Trials Directive and ECTR Terms .............................316
Table 26-3. General Contents of Applications to Ethics Committees and National Competent Authorities ............................................................................................................. 321
Table 26-4. Contents of Clinical Trial Application Dossier per the ECTR .....................................329
Table 26-5. Contents of DSUR .....................................................................................................334
Table 27-1. EU Module 1 Contents .............................................................................................351
Table 27-2. EU eCTD Envelope Information ................................................................................352
Table 29-1. Legal Basis of EU Applications from Directive 2001/83/EC ........................................381
Table 30-1. Data Package Required for a Marketing Authorisation Application to EMA ..............400
Table 31-1. Some Common Health Conditions Treated Using Nonprescription Medication ........405
Table 31-2. Comparison of EU MAA Procedure Advantages and Risks for Nonprescription Medicines ................................................................................................................. 406
Table 34-1. Overview of Good Pharmacovigilance Practices .................................................... 439
Table 35-1. EU Pathways and Expedited Evaluation Programs That Might Apply to ATMPs ......... 453
Table 35-2. ATMPs That Have Been Granted a Marketing Authorisation in the EU ....................455
Table 35-3. Recent Examples of CAT ATMP Classifications .......................................................457
Table 36-1. Serological Donor Testing Requirements ..................................................................475
Table 36-2. Structure of the Single European Code .....................................................................476
Table 36-3. Qualifications and Responsibilities of the Responsible Person Under the EUTCD, Qualified Person for Human Medicinal Products and Responsible Person for Regulatory Compliance Under the EU MDR ................................................................................................................ 479
Table 36-4. Standard Timetable for Initial ATMP Marketing Authorisation Application Evaluation Under the Centralised Procedure ................................................................. 481
Table 40-1. Medicinal Products Derived From Human Plasma and Their Indications ..................521
Table 43-1. EMA’s Committees and Working Parties ................................................................. 558
Table 43-2. National Competent Authorities .............................................................................. 562
Table 43-3. Eligible Industry Stakeholder Organisations ............................................................. 565
Table 43-4. EDQM Databases ................................................................................................... 567